معرفی
Professor Amir Abdollahi serves as Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg since June 2023 and leads the Translational Radiooncology program at University Hospital Heidelberg (UKHD), affiliated with Heidelberg University's Faculty of Medicine.
His research focuses on developing next-generation precision oncology through integration of particle therapy innovations from the Heidelberg Ion-Beam Therapy Center (HIT) with advanced molecular tumor-fighting systems. His multidisciplinary team operates within NCT Heidelberg's core focus areas of precision diagnostics and local/systemic immunooncology.
Key research domains include:
- Precision Oncology
- Radiation Oncology and Particle Therapy
- Immunooncology
- Tumor Microenvironment Reprogramming
- Molecular Targeted Therapy
Professor Abdollahi established Heidelberg's translational radio-oncology program and coordinates national efforts through the German Consortium for Translational Cancer Research (DKTK). His work aims to reprogram tumor immunological microenvironments to develop personalized curative cancer therapies, leveraging multidisciplinary collaboration across NCT Heidelberg's specialized research platforms.
